UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?—Case series and review of the literature

European journal of cancer (1990), 2021-08, Vol.153, p.86-95

2021

Volltextzugriff (PDF)

Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306

Annals of surgical oncology, 2020-07, Vol.27 (7), p.2389-2401

2020

Volltextzugriff (PDF)

Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial

Frontiers in oncology, 2022-02, Vol.12, p.751453-751453

2022

Volltextzugriff (PDF)

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy

Cancers, 2022-01, Vol.14 (3), p.526

2022

Volltextzugriff (PDF)

Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial

European journal of cancer (1990), 2020-09, Vol.137, p.250-259

2020

Volltextzugriff (PDF)

Key Prognostic Factors Create a Composite Risk Score to Stratify Patients into High- and Low-Treatment Benefit Groups: A Multicenter, Retrospective Data Analysis of 84 Metastatic Colorectal Cancer Patients Treated with Regorafenib as Part of the CORRECT and CONSIGN Trials

Oncology research and treatment, 2023-09, Vol.46 (9), p.348

2023

Volltextzugriff (PDF)

Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial

BMC cancer, 2015-04, Vol.15 (1), p.237-237, Article 237

2015

Volltextzugriff (PDF)

Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial

Oncotarget, 2017-10, Vol.8 (46), p.80156-80166

2017

Volltextzugriff (PDF)

Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment)

Anti-cancer drugs, 2014-02, Vol.25 (2), p.212-218

2014

Volltextzugriff (PDF)

Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3

Tumor biology, 2015-04, Vol.36 (4), p.2631-2640

2015

Volltextzugriff (PDF)

Toxic epidermal necrolysis after pemetrexed and cisplatin for non-small cell lung cancer in a patient with sharp syndrome

Onkologie, 2012, Vol.35 (12), p.783-786

2012

Volltextzugriff (PDF)

In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media

Cancer imaging, 2013-12, Vol.13 (4), p.557-566

2013

Volltextzugriff (PDF)

Consensus molecular subtypes and RAS status as biomarker of treatment intensity with fluoropyrimidine, bevacizumab, and irinotecan in metastatic colorectal cancer (XELAVIRI, AIO KRK 0110)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3552-3552

2021

Volltextzugriff (PDF)

Treatment responses and disease dynamics in patients with untreated metastatic colorectal cancer receiving bevacizumab-based sequential versus combination chemotherapy: Analysis of a phase 3 trial (AIO KRK0110, XELAVIRI study)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3571-3571

2021

Volltextzugriff (PDF)

Frameless single robotic radiosurgery of pulmonary metastases in colorectal cancer patients

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e15147-e15147

2016

Volltextzugriff (PDF)

Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Final results of the phase 1/2 TREAT-ME-1 trial

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14648-e14648

2019

Volltextzugriff (PDF)

Prognostic importance of primary tumor resection and synchronous metastasis on overall survival in metastatic colorectal cancer: Data from the FIRE-3 (AIO KRK-0306) study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4070-4070

2020

Volltextzugriff (PDF)

Association of MAPK signaling subtypes with prognostic benefit for bevacizumab in left-sided metastatic colorectal cancer (mCRC) patients treated with FOLFIRI + cetuximab / bevacizumab (FIRE-3 trial)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3584-3584

2019

Volltextzugriff (PDF)

Right-sided colorectal cancer (RC): Response to first-line chemotherapy in FIRE-3 (AIO KRK-0306) with focus on early tumor shrinkage (ETS) and depth of response (DpR)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3586-3586

2017

Volltextzugriff (PDF)

TREAT-ME 1: Treatment of advanced gastrointestinal cancer in a clinical phase I/II trial with genetically modified mesenchymal stem cells

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS3122-TPS3122

2014

Volltextzugriff (PDF)

TREAT-ME 1: Treatment of advanced gastrointestinal cancer in a clinical phase I/II trial with genetically modified mesenchymal stem cells: Clinical results of a phase I study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e13535-e13535

2015

Volltextzugriff (PDF)

Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS3097-TPS3097

2015

Volltextzugriff (PDF)

Therapiesequenz beim metastasierten kolorektalen Karzinom

InFo Hämatologie + Onkologie, 2020-03, Vol.23 (3), p.15-21

2020

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(26)

Sprache

Englisch
(25)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?—Case series and review of the literature

Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306

Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy

Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial

Key Prognostic Factors Create a Composite Risk Score to Stratify Patients into High- and Low-Treatment Benefit Groups: A Multicenter, Retrospective Data Analysis of 84 Metastatic Colorectal Cancer Patients Treated with Regorafenib as Part of the CORRECT and CONSIGN Trials

Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial

Corrigendum to ‘Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial’. [European Journal of Cancer 137 (2020) 250–259]

Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study)

Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial

Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment)

Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3

Toxic epidermal necrolysis after pemetrexed and cisplatin for non-small cell lung cancer in a patient with sharp syndrome

In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media

Consensus molecular subtypes and RAS status as biomarker of treatment intensity with fluoropyrimidine, bevacizumab, and irinotecan in metastatic colorectal cancer (XELAVIRI, AIO KRK 0110)

Treatment responses and disease dynamics in patients with untreated metastatic colorectal cancer receiving bevacizumab-based sequential versus combination chemotherapy: Analysis of a phase 3 trial (AIO KRK0110, XELAVIRI study)

Frameless single robotic radiosurgery of pulmonary metastases in colorectal cancer patients

Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Final results of the phase 1/2 TREAT-ME-1 trial

Prognostic importance of primary tumor resection and synchronous metastasis on overall survival in metastatic colorectal cancer: Data from the FIRE-3 (AIO KRK-0306) study

Association of MAPK signaling subtypes with prognostic benefit for bevacizumab in left-sided metastatic colorectal cancer (mCRC) patients treated with FOLFIRI + cetuximab / bevacizumab (FIRE-3 trial)

Right-sided colorectal cancer (RC): Response to first-line chemotherapy in FIRE-3 (AIO KRK-0306) with focus on early tumor shrinkage (ETS) and depth of response (DpR)

TREAT-ME 1: Treatment of advanced gastrointestinal cancer in a clinical phase I/II trial with genetically modified mesenchymal stem cells

TREAT-ME 1: Treatment of advanced gastrointestinal cancer in a clinical phase I/II trial with genetically modified mesenchymal stem cells: Clinical results of a phase I study

Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma

Therapiesequenz beim metastasierten kolorektalen Karzinom

Suchergebnisse filtern